SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on February 1, 2012. The filing reports on a press release issued on the same date regarding the company's diagnostic test for appendicitis, known as AppyScore. Note: The request metadata referenced "Riot Platforms, Inc.," but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational milestones rather than financial performance data.
Material Changes and Operational Updates
- AppyScore Milestones: The company announced anticipated milestones for 2012 related to its AppyScore diagnostic test.
- Clinical Trial Timeline: Management indicated that a pivotal clinical trial for the appendicitis test is expected to begin in mid-2012.
Guidance, Outlook, and Risks
Management commentary is limited to the timeline for the pivotal clinical trial. The filing does not contain specific financial guidance, risk factor updates, or details on contingencies beyond the operational schedule for the AppyScore test.
Key Facts for Investor Verification
- Verify the exact start date of the pivotal clinical trial for the AppyScore test against the "mid-2012" projection.
- Review the full text of the press release (Exhibit 99.1) for specific details on the 2012 milestones.
- Confirm the company's current cash position and funding status, as this 8-K does not disclose liquidity metrics.
- Ensure the correct registrant (AspenBio Pharma, Inc.) is being analyzed, as the metadata contained a discrepancy.